Elevance Health arrives at its July 15 Q2 print with analysts in a clear upgrading mood, but the stock has quietly given back ground since the previous article, putting the Street's conviction to the test.
The most notable pre-earnings move has been in analyst targets. RBC Capital raised its target to $439 from $358 on July 9 — the freshest signal yet — joining a crowd that already includes Bernstein at $482, Barclays at $480, and JPMorgan at $476. The consensus mean has edged to $431, now sitting above the current price of $416.23. That gap between where the stock trades and where analysts think it should go has actually widened slightly since last week's close of $418.85. The lone hold-out remains Morgan Stanley at $404 Equal-Weight, a valuation anchor that increasingly looks like the Street's floor rather than its midpoint.
Options positioning does nothing to suggest investors are bracing for a violent move. The put/call ratio runs at 0.81, almost exactly in line with its 20-day average of 0.81 and well inside its 52-week range of 0.60–0.91. There is no meaningful skew toward downside protection here. Borrow conditions echo the same relaxed tone — availability is exceptionally loose at over 7,200%, meaning shares to borrow vastly outnumber those already shorted. Short interest has edged up roughly 5% over the past month to 2.8% of the free float, but that is a modest level with no squeeze dynamic anywhere in the data. Borrowing costs have ticked up around 42% week-on-week to 0.47%, though in absolute terms that remains firmly in "easy borrow" territory.
The bull and bear cases converge on the same few numbers. Bulls see Medicare Advantage margins expanding more than 150 basis points in 2026 and point to improving D-SNP membership mix as structural support. The April print already validated part of that thesis — the stock jumped 5.5% on the day and extended to nearly 15% over the following week, the strongest post-earnings reaction in recent history. Bears argue the Medicaid drag is structural rather than transitional, with EPS estimates for 2026 trimmed to $25.54 and commercial market pressures still unresolved. A PE of roughly 13.7x and EV/EBITDA near 10.5x are not demanding multiples for a business this size, which partially explains why shorts have not pressed harder even as the stock recovered.
The July 15 print is therefore less about whether Elevance can grow and more about whether the Medicare Advantage margin story holds at the pace the Street has now priced in — and whether any Medicaid surprise, positive or negative, changes the trajectory of the 2026 EPS estimates that bulls need to defend.
See the live data behind this article on ORTEX.
Open ELV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
